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Abstract 
Background: The Baveno VI guidelines propose that cirrhotic patients with a liver stiffness 
measurement (LSM) <20kPa and a platelet count >150000/µL can avoid screening 
endoscopy as their combination is highly specific for excluding clinically significant varices. 
The aim of the study was to validate these criteria. 
Methods: Transient elastography data was collected from two institutions from 2006-2015. 
Inclusion criteria were a LSM ≥10kPa and an upper gastrointestinal endoscopy within 12 
months, with a diagnosis of compensated chronic liver disease. Exclusion criteria were 
porto-mesenteric-splenic vein thrombosis and non-cirrhotic portal hypertension. Varices 
were graded as low risk (grade <2) or high risk (grade ≥2). 
Results: The study included 310 patients (169 (55%) hepatitis C, and 275 (89%) Child Pugh 
A). Varices were present in 23% cases, with 5% prevalence of high risk varices. Overall 
102/310 (33%) met the Baveno VI criteria. Within this group 11% had varices and 2% had 
high risk varices, representing 2/15 (13%) of all high risk varices. The Baveno VI criteria 
gave a sensitivity 0.87, specificity 0.34, positive predictive value 0.06, negative predictive 
value 0.98, positive likelihood ratio 1.31 and negative likelihood ratio 0.39. The AUROC for 
LSM and platelet count combined was 0.746. 
Conclusions: The Baveno VI criteria performed well correctly identifiying 98% of patients 
who could safely avoid endoscopy.  
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Lay Summary 
This study examines the effectives of a recent set of guidelines published by the Baveno VI 
conference, which states that patients with chronic liver disease and a low liver stiffness 
(<20kPa) and high platelet count (>150) are at low risk of having varices and do not need a 
screening endoscopy. Varices are a complication of cirrhosis, confer a risk of serious 
bleeding, and can be diagnosed and treated by endoscopy. Our study reviewed the clinical 
records of patients who have had liver stiffness scans and endoscopy over a 9 year period 
at two hospitals. The results show that only about 2% of patients who meet the Baveno VI 
criteria will be miss classified as not having varices. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Introduction 
Gastroesophageal varices occur as a consequence of portal hypertension and are a 
major cause of morbidity and mortality due to the risk of haemorrhage. In cirrhosis raised 
portal pressures initially develop as a result of advanced fibrosis and deranged liver 
architecture, but as liver disease progresses additional haemodynamic factors, such as 
splanchnic vasodilatation and hyperdynamic circulation, become increasingly important 
(Vizzutti et al. 2007). Portal pressures have traditionally been measured using hepatic 
venous pressure gradient (HVPG), and an HVPG ≥ 10mmHg confers increased risk of 
developing gastroesophageal varices (Groszmann et al. 2005). HVPG has been shown to 
correlate well with the presence and size of varices (Wadhawan et al. 2006), however 
measuring portal pressures by HVPG is invasive and limited to the centres with the relevant 
expertise. 
Over the last decade transient elastography (TE) has become a widely used, non- 
invasive measure of liver stiffness and fibrosis. Following initial studies showing its accuracy 
in diagnosing significant fibrosis its clinical applications have been widened. The use of TE 
as a surrogate marker of portal hypertension has been demonstrated by liver stiffness 
measurement (LSM) correlating well with portal pressures up to a HVPG of 10-12mmHg 
(Vizzutti et al. 2007)(Bureau et al. 2008). Subsequent data has shown that TE is of potential 
benefit in the non- invasive diagnosis of varices, especially when TE is combined with other 
markers such as platelet count and spleen size (Berzigotti et al. 2013).  
A major limitation to implementing these tests into clinical practice for diagnosing 
gastroesophageal varices has been an inadequate specificity. As a result the diagnostic 
strength of non- invasive investigations such as TE have not yet been sufficient to replace 
endoscopy in the diagnosis of varices (Shi et al. 2013) (EASL 2015), and all patients with 
  
cirrhosis currently require routine surveillance with frequent oesophagogastroduodenoscopy 
(OGD).  
The promising sensitivity and negative predictive value of TE, especially in 
combination with other non- invasive markers, means these investigations may be more 
effective tools at identifying low risk cirrhotic patients who can be safely ‘ruled out’ of 
needing an endoscopy. The recent Baveno VI guidelines acknowledge this application and 
recommend that in patients with compensated advanced chronic liver disease (cACLD) a 
LSM <20Kpa and a platelet count > 150,000 cells/µL have a very low risk of having varices 
requiring treatment and therefore do not require screening endoscopy. They advise 
longitudinal follow-up of such patients by annual repetition of TE and platelet count with the 
guidance that if liver stiffness increases or platelet count declines to within the 
recommended values, these patients should undergo screening OGD (de Franchis 2015).  
 In this retrospective cross-sectional cohort study, we reviewed all patients over a nine 
year period at two centres who have undergone clinical, laboratory, TE and endoscopic 
evaluation of portal hypertension. The primary aim was to validate the recently proposed 
Baveno VI criteria and assess their sensitivity at accurately identifying those patients who 
can safely avoid screening endoscopy. Secondary aims were to assess if the criteria had 
similar sensitivities across all aetiologies of chronic liver disease, given the majority of 
published data is from patients with viral hepatitis, and to identify if alternative LSM or 
platelet parameters should be recommended. 
Methods 
Study Population 
This is a retrospective cohort study. Transient elastography data collected from two 
institutions from November 2006 - September 2015 were analysed. All patients with a LSM 
≥ 10kPa were selected. Additional inclusion criteria were an OGD within 12 months of TE, 
and a diagnosis of chronic liver disease. Exclusion criteria were decompensated disease 
  
(defined as Child Pugh C disease or Child Pugh B with evidence of ascites, encephalopathy 
or previous variceal haemorrhage), current use of non- selective beta- blockers, porto-
mesenteric-splenic vein thrombosis, and non-cirrhotic portal hypertension. A sub-analysis of 
all patients with OGD within 6 months of TE was also performed. 
 
Transient Elastography 
All TE was performed using Fibroscan© (Echosens, Paris) by experienced practitioners at 
two large specialist centres who follow conventional practice. Patients were fasted for two 
hours before the procedure. All patients were examined in the standard way with the right 
lobe of the liver accessed by the patient lying in the dorsal cubitus position and maximal 
abduction of the right arm. Ten valid measurements were obtained and a median LSM value 
(kPa) generated. Inadequate LSM (defined by interquartile range >30% and success <60%) 
were excluded. 
Assessment of varices 
All patients had an OGD within 12 months of the TE. Gastroesophageal varices were 
defined as low risk varices (LRV) or high risk varices (HRV). For the purpose of this study all 
varices that were described as < grade 2 were defined as LRV. Conversely all oesophageal 
varices described as ≥ grade 2, and any gastric varices, were defined as HRV. This 
differentiation was made as all varices classified as high risk in this way would be deemed 
clinically significant and require treatment in standard clinical practice.  
Laboratory Investigations 
Laboratory investigations were collected, including platelets, bilirubin, alanine 
aminotransferase, aspartate aminotransferase, albumin, international normalised ratio 
(INR), sodium and creatinine. 
Statistical analysis 
  
Demographic and laboratory data was summarised and compared between patients with 
and without HRV. Continuous variables were reported as medians with interquartile range, 
and compared using Mann-Whitney test. The variables of LSM and platelet count were 
compared to the binary outcome measure of the presence of HRV. Sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio 
(LR+) and negative likelihood ratio (LR-) were calculated as per the cut offs recommended 
by Baveno VI (de Franchis 2015). AUROC values were generated for the presence of HRV, 
using the variables of LSM, platelet count and the two variables combined. 
Statistics were performed using the software packages SPSS. 
Results 
Study population 
Over the study period 12331 transient elastography (TE) scans were performed. After 
excluding inadequate scans, values <10kPa, and multiple scans on the same patient and 
scans without an OGD within 12 months, 391 cases remained. Of these, a further 81 were 
excluded: n=10 non-cirrhotic portal hypertension, n=5 portal/mesenteric/splenic vein 
thrombosis, n=13 current use of non- selective beta blockers, n=53 decompensated 
disease. In total 310 patients were included in the study (Figure 1). 
Demographic data 
Of the 310 cases that met the inclusion criteria for the study, 209 (67%) were male and 101 
(33%) female. The aetiology of the underlying liver disease was hepatitis C ( HCV, n=169 
(55%)), alcohol- related liver disease (ALD, n=40 (13%)), non-alcoholic fatty liver disease 
(NAFLD, n=42 (14%)), Hepatitis B/D (HBV, n=24 (8%)), and other (n=35 (11%): ALD/HCV 
(n=5), HBV/NAFLD (n=1), HBV/HCV (n=2), ALD/NAFLD (n=2), drug reaction (n=2), 
cryptogenic (n=4), Gaucher’s/HCV (n=1), Gaucher’s (n=1), haemochromatosis (n=2), 
haemochromatosis/HCV (n=1), sarcoidosis (n=1), sarcoidosis/HBV/HCV (n=1), autoimmune 
  
hepatitis (n=2), primary biliary cholangitis (n=4), primary sclerosing cholangitis (n=5), 
overlap syndrome (n=1)). One case with ALD had alcoholic hepatitis at the time of transient 
elastography, with a LSM 16.8kPa. The majority of cases were Child Pugh A (n=275 
(89%)), with 35 cases (11%) Child Pugh B. Median MELD score was 7. The above data is 
summarised in Table 1. 
Varices were present in 18% of the population studied (n=57); 15 patients (5%) had HRV. 
Two cases had high risk stigmata with red wale signs. With respect to LSM, 167 (54%) 
cases had a LSM <20kPa, and 143 (46%) cases had a LSM ≥ 20kPa. In laboratory tests 
151 (49%) cases had platelets >150x103/ml, and 159 (51%) had platelets ≤150x103/ml 
(Table 1, 2a and 2b). 
 
Liver stiffness measurement as a predictor of varices 
The median LSM in our cohort was 18.4kPa. As expected liver stiffness measurement was 
significantly higher in patients with HRV than in those without HRV (26.0kPa vs 18.4kPa, 
p<0.015). In the cases with LSM <20kPa, 23/167 (14%) had any varices, of which 5 (3%) 
were HRV. Of the cases with LSM ≥20kPa, 49/143 (34%) had any varices, of which 10 (7%) 
had HRV (Table 2a).  Overall for identifying HRV, LSM cut- off of 20kPa had a sensitivity of 
0.67, specificity 0.55, positive predictive value (PPV) 0.07, negative predictive value (NPV) 
0.97, positive likelihood ratio (LR+) 1.48 and negative likelihood ratio (LR-) 0.61 (Table 3a).  
The AUROC for LSM as an independent variable was 0.686 (Supplementary Fig 1). 
Platelet value as a predictor of varices 
The median platelet count in our cohort was 147000/µL, and was not significantly lower in 
patients with HRV than in those without HRV. In cases with platelets >150000/µL, 22/151 
(15%) had any varices, and of these 6 (4%) were HRV. In cases with platelets ≤150000/µL, 
50/159 (31%) had any varices, of which 9 (6%) were HRV (Table 2a). Overall for identifying 
  
HRV, platelet count cut-off of 150000/µL had a sensitivity of 0.60, specificity 0.49, PPV 0.06, 
NPV 0.96, LR+ 1.18, LR- 0.81 (Table 3a). The AUROC for platelets as an independent 
variable was 0.599 (Supplementary Fig 1). 
Baveno VI Criteria as a predictor of varices 
The Baveno VI consensus guidelines combine LSM < 20kPa and platelet count 
>150000/µL. In this cohort, 102/310 (33%) cases met these criteria, of whom 11 (11%) had 
any varices and 2 (2%) had HRV. Among the 208/310 (67%) cases that fell outside of the 
Baveno VI criteria, 61/208 (29%) had any varices and 13 (6%) had HRV (Table 2a). 
Combining LSM and platelet count using the recommended cut-off values to detect HRV 
gives a sensitivity 0.87, specificity 0.34, PPV 0.06, NPV 0.98, LR+ 1.31, LR- 0.39 (Table 
3a). The AUROC for the combination of LSM and platelets was 0.746 (Supplementary Fig 
1). Using the Baveno VI guideline 2/15 (13%) of HRV were missed (Figure ). The LSM and 
platelet count of these cases were 16.8kPa / 380000/µL and 17.6kPa / 160000/µL 
respectively. Both cases had grade 2 oesophageal varices and compensated cirrhosis 
secondary to HCV. 
 
Impact of aetiology on diagnostic accuracy 
Out of the 15 cases with HRV, 11 had viral hepatitis and 2 cases had ALD and NAFLD. In a 
sub analysis by aetiology, the Baveno VI guidelines in viral hepatitis had a sensitivity 0.82, 
specificity 0.28, PPV 0.06, NPV 0.96, LR+ 1.13 and LR- 0.66; in NAFLD/ ALD, they had a 
sensitivity 1.00, specificity 0.45, PPV 0.04, NPV 1.0, LR+ 1.82 and LR- 0.00 (Table 4). 
AUROC for TE, platelets and the two variables combined in viral hepatitis was 0.633, 0.675 
and 0.749 and in ALD/NAFLD were 0.924, 0.534 and 0.927 respectively (Supplementary 
Fig 1). 
Impact of Time between OGD and Transient Elastography 
2
  
The above analysis was repeated in a population restricted to patients who had an OGD 
within 6 months of transient elastography. This included a slightly smaller (n=219) cohort 
with similarly mixed aetiology (HCV n=118). In this analysis, 66/219 patients met BAVENO 
VI criteria for avoiding screening endoscopy, of whom 1 case had high risk varices. The 
diagnostic performance of the BAVENO VI criteria was similar in this sub-group as for the 
whole study population (Table 2b and 3b). 
 
Discussion 
In this large dual centre cross- sectional cohort study we validate the recently published 
BAVENO VI guidelines for using non-invasive criteria in patients with cACLD to identify 
patients who are at low risk of clinically significant varices and thus can safely avoid 
screening endoscopy. We have demonstated that applying such criteria will reduce the 
number of surveillance endoscopies by about 30%, but could incorrectly classify 2% of 
patients. Thus adherence to these criteria may delay clinically effective prophylaxis against 
variceal bleeding with non-selective beta-blockers in a small proportion of patients.  
The study included 310 patients. Hepatitis C was the most common aetiology, but 
with a prevalence of just 55% our cohort reflects a more heterogenous group compared to 
many of the large studies in this field of predominantly HCV populations (Augustin et al. 
2014)(Berzigotti et al. 2013).  
 The prevalence of all GOV was 23% (18% LRV and 5% HRV). The combination of 
TE and platelet count with the cut-off values proposed by Baveno VI had a high NPV and 
low LR-, in contrast to poor PPV and LR+, confirming these markers perform more strongly 
at ‘ruling out’ rather than ‘ruling in’ HRV, in keeping with the guidelines.  A total of 2/15 
(13%) cases with HRV had platelets >150 and TE <20kPa and were miss-classified by 
Baveno VI. Application of the guidelines will have excluded these patients from endoscopic 
surveillance and delayed the introduction of appropriate primary prophylaxis. However, on 
  
detailed examination of the two cases one had thalassaemia major and also a splenectomy 
in 1975, which may explain the unusual finding of platelets in the upper limit of normal in the 
context of cACLD. Careful consideration must therefore be given to co-morbidities which 
may impact the validity of the proposed platelet cut-off. 
Reassuringly only 2/102 (2%) cases meeting BAVENO criteria had HRV, therefore 
the annual risk to a patient counselled in clinic based on a bleeding rate from varices of 15% 
per year would be just 0.3% (Garcia-tsao et al. 2007). The guidelines however advise 
annual assessment of TE and platelet count, followed by endoscopic surveillance of 
patients who move out of the low risk category. In the miss-classified patients, sequential 
annual platelet counts were 160000 – 195000 – 188000/µL (HCV, no known haematological 
co-morbidities) with no further TE data, and 380- 298- 307- 337 (HCV with thalassaemia 
major and previous splenectomy) with progression in liver stiffness from 16.8kPa to 20kPa 
on repeat TE four years later. Further longitudinal prospective data will help define the 
actual risk of bleeding by applying the Baveno VI criteria and if there is an increase 
compared to current practice due to the inevitable small percentage of high risk varices that 
will not be captured using non-invasive markers.  
Applying the data from our cohort, a reduction in the LSM cut-off to 16.8kPa would 
have resulted in the inclusion of both the miss-classified cases for endoscopic surveillance. 
Incorporating this cut-off into the Baveno VI criteria would have correctly identified all 
patients who could safely avoid screening endoscopy. This would be just below the median 
LSM 18.4kPa in our cohort and similar to the mean LSM 17.6kPa in a study of compensated 
cirrhotic patients with no cases of HRV (Augustin et al. 2014), but would result in an 
additional 27 (13%) endoscopies in our cohort. 
The rationale for the Baveno VI guidelines comes from evidence in a number of 
studies demonstrating that non- invasive investigations such as TE and platelet count show 
promise in the diagnosis of varices, but generally perform better at excluding rather than 
  
diagnosing high risk varices. A study by Berzigotti et al in compensated cirrhotics showed 
that TE, in combination with platelet count and spleen size, had a NPV 0.95 and LR- 0.13 
compared to PPV 0.55 and LR+ 2.63 when the cut-off was set for a sensitivity of 
90%(Berzigotti et al. 2013). Similarly Stefanescu et al showed that TE combined with 
additional serological and radiological markers produced a NPV 1.0 and LR- 0.1 for high risk 
oesophageal varices (Stefanescu et al. 2014). More recently Perezzo et al focussed on TE 
and platelet count as in the Baveno VI guidelines in a prospective assessment 99 HCV 
cirrhotic patients (80% Child Pugh A, 63% female): 14% had HRV, all of which were 
appropriately classified by the Baveno VI criteria. Spleen stiffness did not improve the 
performance of TE and platelet count to identify low risk patients (Perazzo et al. 2015).  
Four aspects of our results should be commented on: firstly, these data suggest 
there is a role for non- invasive markers in identifying patients at low risk of having clinically 
significant varices who can safely avoid screening endoscopy. Our reported NPV of 0.98 is 
similar to the NPV of troponin, which is widely implemented to exclude the diagnosis of 
myocardial infarction (Al-Saleh et al. 2014). This presents an opportunity to reduce the 
burden of unnecessary endoscopies for patients who often face many invasive 
investigations through the course of their disease, but the poor PPV and LR+ show these 
non- invasive tests cannot replace endoscopy in the diagnosis of varices and deciding 
which patients warrant treatment with primary prophylaxis. Secondly, the guidelines offer 
single cut-off values that do not account for underlying aetiology. They do acknowledge that 
the majority of the work in this area has been in chronic hepatitis C, and the value of TE in 
diagnosing clinically significant portal hypertension in other aetiologies remains to be 
ascertained. Reassuringly in our small sub group of ALD and NAFLD cases no HRV were 
missed by the Baveno VI criteria. This is in keeping with some recent studies which have 
also investigated the use of TE for diagnosing gastroesophageal varices in heterogenous 
populations(Ding et al. 2015) (Stefanescu et al. 2014). However, further research is needed 
to validate these non-invasive markers in other aetiologies, particularly NAFLD and ALD. 
  
Thirdly, the data leading to the current guidelines is drawn from populations with variable 
disease severity and prevalence of varices. The overall prevalence of HRV in our cohort is 
5%, and 2% in the cohort meeting the Baveno VI low risk criteria, which is higher than in a 
study of carefully chosen compensated cirrhotics that found a 0% prevalence of HRV 
(Augustin et al. 2014), but somewhat lower than in  an earlier meta- analysis of TE in 
detecting large varices that quoted higher prevalence rates ranging from 14.7 to 48% (Shi et 
al. 2013). We agree with the Baveno VI statement that the guidelines should only be applied 
to a population with early, well compensated disease with a low pre-test probability of 
varices and therefore with a low chance of missing cases requiring treatment. Finally, 
Baveno VI elected to use TE and platelet count alone. Many of the studies on the non- 
invasive assessment of varices have used additional serological and radiological markers 
such as spleen stiffness, platelet- spleen ratio, spleen size and Lok score, which can 
improve the accuracy of diagnosing varices when used in combination with TE (Takuma et 
al. 2013)(Stefanescu et al. 2014)(Berzigotti et al. 2013). While the results of our study are 
promising for the simple, pragmatic use of just TE and platelet count, cases will be missed 
which will have implications, albeit small, on bleeding risk. Most of these additional non- 
invasive markers are readily available and could be useful in further refining the accuracy of 
the diagnostic algorithm. 
This study has some limitations. The retrospective design brings inherent limitations 
of bias, which is a particular factor in the high number of cases that did not have an OGD 
within 12 months of a transient elastography result demonstrating advanced fibrosis. We 
think this is probably due to a clinical suspicion of mild disease, reflected in a lower median 
LSM 15.3kPa in the patients not eventually included, compared to 17kPa in the study 
population (p<0.001). Endoscopy was not performed simultaneously with the TE, with a 
median duration of time between TE and endoscopy of 120 days. However, this is well 
below the recommended annual surveillance frequency of high- risk patients without 
varices, and repeating the analysis on only patients endoscoped within 6 months did not 
  
significantly alter the results (Table 2b and 3b). Moreover, using the presence of varices as 
an endpoint is limited by variable and subjective reporting of their size. However, this is a 
real world study and initiation of primary prophylaxis is based on the endoscopic evidence of 
high risk varices given the impractical nature of routinely measuring HVPG. Therefore, 
identifying non-invasive techniques to identify patients without varices is directly relevant to 
clinical practice. Finally, we elected to use a relatively conservative cut-off LSM value of 
10kPa for our study cohort based on the Baveno VI definition of patients likely to have 
compensated advanced chronic liver disease. This is below the accepted cut-off value 
13.6kPa for cirrhosis in viral hepatitis, the most heavily studied cohort, and may have 
reduced the prevalence of HRV and elevated the negative predictive value. However, the 
HRV prevalence of 5% is higher than in other studies of compensated cirrhotics (Augustin et 
al. 2014). Moreover, other causes of chronic liver disease such as non- alcoholic liver 
disease are often poorly represented in this field of research, and the LSM criteria for 
cirrhosis in non- viral aetiologies is less well defined. 
Conclusion 
Significant progress has been made in the field on non- invasive markers for diagnosing 
HRV. Our data partly supports the Baveno VI statement that identifying low risk patients 
who do not require surveillance endoscopy is a realistic goal with the current technologies, 
which could produce a significant cost saving and beneficially impact on patient experience. 
However, this data also highlights that a small proportion of cases will be miss-classified 
and thus be denied proven prophylactic therapies for primary prevention of variceal 
bleeding. The risk will be minimised by careful assessment for comorbidities that may affect 
platelet count, and long-term follow-up with annual TE and platelet count to initiate timely 
endoscopic surveillance in suitable patients. Confirmation by prospective, longitudinal data 
collection will give further support to these recommendations. 
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Tables 
Table 1: Cohort demographics.  Data expressed as median values with interquartile range unless indicated. 
#
 
p value comparing HRV to No HRV groups using Mann Whitney test. HRV High Risk Varices; LRV Low Risk 
Varices; TE Transient Elastography; LSM Liver Stiffness Measurement. 
Patient Demographics Total n=310 (%) HRV n=15 (5%) No HRV n=295 
(95%) 
p value
#
 
Male (%) 209 (67) 9 (60) 200 (68) - 
Female (%) 101 (33) 6 (40) 95 (32) - 
Age (y) 58 (51, 66)) 56 (49, 67) 57 (51, 66) 0.202 
     
Aetiology     
Hepatitis C (%) 169 (55) 11 (73) 158 (54) - 
Hepatitis B/D (%) 24 (8) 0 (0) 24 (8) - 
Alcohol (%) 40 (13) 1 (7) 39 (13) - 
NAFLD (%) 42 (14) 1 (7) 41 (14) - 
Miscellaneous (%) 35 (11) 2 (13) 33 (11) - 
     
Time (days) between 
OGD and TE 
120 (53, 208) 83 (53, 261) 120 (51, 204) 0.927 
     
Child Pugh Score     
A (%) 275 (89) 13 (87) 262 (89) - 
B (%) 35 (11) 2 (13) 33 (11) - 
  
MELD Score 7 (6, 9) 8 (7, 12) 7 (6. 9) 0.073 
     
LSM (kPa)
#
 18.4 (13.6, 27.9) 26.0 (17, 71) 18.4 (13.2, 27.7) 0.015* 
     
Nodules (%) 15 (5) 0 (0) 15 (5)  
Benign 9 (3) - 9 (3)  
HCC 6 (2) - 6 (2)  
     
Laboratory Results     
Platelets (cells x10
3
/μL) 147 (101, 198) 133 (59, 197) 147 (102, 199) 0.197 
Alanine 
aminotransferase (U/L) 
64 (38, 104) 91 (49, 102) 64 (38, 105) 0.303 
Aspartate 
aminotransferase (U/L) 
67 (40, 113) 102 (69, 133) 65 (40, 111) 0.081 
Bilirubin (μm/L) 13 (9,18) 21 (14, 23) 12 (9, 17) 0.006* 
Albumin (g/L) 41 (37, 44) 39 (34, 42) 41 (37, 44) 0.045* 
Sodium (mmol/L) 140 (138, 142) 141 (139, 141) 140 (138, 142) 0.375 
Creatinine (μmol/L) 73 (64, 86) 74 (62, 81) 73 (64, 87) 0.959 
INR 1.1 (1.0, 1.2) 1.1 (1.1, 1.2) 1.1 (1.0, 1.2) 0.027* 
     
GOV     
None (%) 238 (77)    
LRV 57 (18)    
HRV 15 (5)    
All varices 72 (23)    
 
Table 2a: Prevalence of all varices and high risk varices in groups generated by the recommended cut-off 
values from Baveno VI. LSM Liver stiffness measurement. 
Variable Any Varices High Risk Varices 
 Yes No Yes No 
  
LSM<20kPa (n=167) 23 144 5 162 
LSM≥20kPa (n=143) 49 94 10 133 
     
Platelets≤150x10
3
/μL
 
(n=159) 
50 109 9 150 
Platelets>150x103/μL  (n= 
151) 
22 129 6 145 
     
Within Baveno VI criteria: 
LSM<20kPa and 
Platelets>150x10
3
/μL 
(n=102) 
11 91 2 100 
Outside Baveno VI criteria: 
LSM≥20kPa and/or 
Platelets≤150x10
3
/μL(n=208) 
61 147 13 195 
 
Table 2b: Prevalence of all varices and high risk varices in groups generated by the recommended cut-off 
values from Baveno VI. Sub-analysis of population with OGD within 6 months of LSM. LSM: Liver stiffness 
measurement; OGD: oesophagogastroduodenoscopy. 
Variable Any Varices High Risk Varices 
 Yes No Yes No 
LSM<20kPa (n=112) 20 92 4 108 
LSM≥20kPa (n=107) 35 72 6 101 
     
Platelets≤150x10
3 
/μL
 
(n=118) 
41 77 8 110 
Platelets>150x10
3 
/μL 
(n= 101) 
14 87 2 99 
     
Within Baveno VI 
criteria: LSM<20kPa and 
Platelets>150x103 /μL 
(n=66) 
9 57 1 65 
Outside Baveno VI 
criteria: LSM≥20kPa 
and/or 
46 107 9 144 
  
Platelets≤150x10
3
 /μL
 
(n=153) 
 
 
Table 3a: Performance of each variable for diagnosing high risk varices. LSM liver stiffness measurement; 
PPV positive predictive value; NPV negative predictive value; LR+ positive likelihood ratio; LR- negative 
likelihood ratio. 
Variable 
(Cut-off value) 
Sensitivity Specificity PPV NPV LR+ LR- 
       
LSM (20kPa) 0.67 0.55 0.07 0.97 1.48 0.61 
       
Platelets 
(150x103/μL) 
0.60 0.49 0.06 0.96 1.18 0.81 
       
Baveno VI criteria 
[LSM (20kPa) and 
Platelets 
(150x10
3
/μL)] 
0.87 0.34 0.06 0.98 1.31 0.39 
 
Table 3b: Performance of each variable for diagnosing high risk varices. Sub-analysis of population with 
OGD within 6 months of LSM. OGD: oesophagogastroduodenoscopy; LSM: liver stiffness measurement; PPV 
positive predictive value; NPV negative predictive value; LR+ positive likelihood ratio; LR- negative likelihood 
ratio. 
Variable 
(Cut-off value) 
Sensitivity Specificity PPV NPV LR+ LR- 
       
LSM (20kPa) 0.60 0.52 0.06 0.94 1.24 0.77 
       
Platelets 
(150x10
3
/μL) 
0.80 0.47 0.07 0.98 1.52 0.42 
       
Baveno VI criteria 
[LSM (20kPa) and 
Platelets 
0.90 0.31 0.06 0.98 1.31 0.32 
  
(150x10
3
/μL)] 
 
Table 4: The performance of Baveno VI criteria in a sub analysis by aetiology. PPV positive predictive value; 
NPV negative predictive value; LR+ positive likelihood ratio; LR- negative likelihood ratio; NAFLD Non- 
alcoholic fatty liver disease; ALD Alcohol- related liver disease 
Variable  
(Cut-off value) 
Sensitivity Specificity PPV NPV LR+ LR- 
Viral Hepatitis 0.82 0.28 0.06 0.96 1.13 0.66 
       
NAFLD 1.00 0.46 0.04 1.00 1.86 0.00 
       
ALD 1.00 0.41 0.04 1.00 1.70 0.00 
       
ALD/NAFLD 1.00 0.45 0.04 1.00 1.82 0.00 
       
 
 
 
 
 
 
Figures Legends 
Fig. 1: Flow chart of patients evaluated for inclusion in the study  
LSM: Liver Stiffness Measurement; OGD oesophagogastroduodenoscopy; LSM liver stiffness 
measurement; NSBB: pre-existing treatment with non-selective beta blocker; 
 
Fig. 2: Summary prevalence of HRV in the study cohort of low risk and high risk patients as 
defined by the Baveno VI criteria. HRV: high risk varices; LSM: liver stiffness measurement. 
  
  
 
  
  
 
  
  
 
